"Breakthrough Antibiotic Offers Hope Against Drug-Resistant Superbugs"

Researchers at Harvard University and Roche have developed an experimental antibiotic named zosurabalpin that effectively kills the drug-resistant superbug Acinetobacter baumannii. This breakthrough represents a new class of drugs, as it targets Gram-negative bacteria, which are notoriously difficult to treat due to their complex membrane structures and resistance strategies. Zosurabalpin, which is already in clinical trials, works by clogging a transport system in the bacteria, leading to lethal toxicity. This discovery is significant as it offers hope against infections with mortality rates of 40 to 60 percent and could lead to more treatments for drug-resistant infections.